Case Study: 63-Year-Old Man With Multiple Myeloma

News
Video

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.

Recent Videos
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Rendering of red blood cells with multiple myeloma

Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM

Roman Fabbricatore
March 30th 2025
Article

Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Microscope image of multiple myeloma

Older Patients with Lenalidomide-Refractory MM May Face Treatment Gaps

Roman Fabbricatore
March 10th 2025
Article

Real-world data show that older adults with lenalidomide-refractory MM have poor survival outcomes after 1 to 3 lines of therapy.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Simple white line illustration of red blood cells on a yellow background

Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

Ashling Wahner
January 30th 2025
Article

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

an illustration of a bone with circles around it indicating a microscope, test tubes and prescriptions

Subcutaneous Isatuximab Non-Inferior to IV in Relapsed/Refractory Myeloma

Caroline Seymour
January 10th 2025
Article

In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd.